The short answer
Most orally administered drugs are absorbed in the small intestine, not the stomach, so the rate at which the stomach empties governs when absorption begins. Delaying it delays and flattens the peak concentration, which matters most for drugs whose effect depends on reaching a threshold.
Key facts
- Absorption site
- Small intestine, for most oral drugs
- Stomach's role
- Controls delivery rate
- Effect of delay
- Later, lower peak concentration
- Total exposure
- Often less affected than peak
- Most affected
- Threshold-dependent drugs
- Class behaviour
- Not uniform; varies by compound
Why the stomach is a gate rather than an absorber
The gastric mucosa absorbs very little. The small intestine does the work, with a vastly larger surface area and the transporters most drugs rely on. So the stomach functions as a metering valve. It holds contents and releases them onward, and the rate of that release sets when the intestine can begin absorbing.
What slowing the valve does to a concentration curve
Two things, and they are separable. The peak concentration falls, because the same quantity arrives spread over a longer period. And the time to that peak lengthens. Total exposure (the area under the curve) is often less affected, because the drug eventually arrives; it simply arrives more gradually.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the distinction between peak and total matters
It determines which drugs are affected in a way that matters. A drug whose effect tracks total exposure over a day tolerates a flattened peak. A drug that must exceed a concentration threshold to work may fail to reach it. The same pharmacokinetic change is inconsequential for one and consequential for the other.
Why incretin agonists slow gastric emptying at all
It is part of the mechanism rather than a side effect. Slowing gastric emptying prolongs the sensation of fullness and blunts the post-meal glucose rise, both of which contribute to the intended effect. Shaefer and colleagues set this out in their user's guide to the class in Postgraduate Medicine in 2015. Any consequence for co-administered oral drugs follows from the mechanism working.
Why the effect is not uniform across the class
Different compounds delay gastric emptying to different degrees, and the delay also attenuates over time with continued exposure, which is why gastrointestinal effects typically diminish after the first weeks. A compound with a stronger effect, or one escalated rapidly through doses, presents a different interaction picture from one with a milder effect at a steady dose.
What this is and is not
A description of pharmacokinetic principles and published findings about licensed medicines. It is not guidance about taking anything, and no research material supplied here is a GLP-1 receptor agonist or has any bearing on medicines a person may be prescribed.
Frequently asked questions
Where are oral drugs absorbed?
Mostly in the small intestine. The stomach absorbs very little and acts as a metering valve controlling delivery.
Does delayed emptying reduce total drug exposure?
Often less than it reduces the peak. The drug still arrives, just more gradually, so peak concentration falls more than area under the curve.
Which drugs are most affected?
Those that must exceed a concentration threshold to work, rather than those whose effect tracks total daily exposure.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedShaefer CF Jr et al., User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med 2015 (PMID 26371721)pubmed.ncbi.nlm.nih.gov
- PubMedSkelley JW et al., The impact of tirzepatide and GLP-1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc 2024 (PMID 37940101)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- One Compound, Not the Whole ClassTirzepatide reduced peak contraceptive hormone concentrations by 55-66% in reported data. Semaglutide, liraglutide and dulaglutide did not show the effect.
- Where the Thyroid Warning Came FromRodents given GLP-1 agonists developed C-cell hyperplasia and tumours. The 2010 paper that established it, and why it was an on-target effect.
- Normal Human Thyroid Has No Detectable GLP-1 ReceptorsWaser 2011 measured incretin receptors in rodent and human thyroid. The species difference is stark - and the human receptor picture points at GIP, not GLP-1.
- The Strongest Warning a Label CarriesA boxed warning is the most serious labelling a regulator applies. It does not mean a risk is proven - it means the consequence would be severe.
- The Hormone That Empties the Gallbladder, SuppressedCholecystokinin makes the gallbladder contract. GLP-1 suppresses cholecystokinin secretion - which is the identified mechanism behind the biliary events.